Bipolar

Speed Sensor Global Market Report 2022: by Type, Application, End-user and Region

Retrieved on: 
Friday, January 20, 2023
Benchmark, STMicroelectronics, Analog Devices, ABB, Coronavirus, Health, TE, Sensor, Sick AG, Travel, Electronics, Allegro, Maxim Integrated, Infineon Technologies, Growth, Rotation, NXP Semiconductors, India Brand Equity Foundation, Semiconductor industry, Organization, Rockwell Automation, Create, Acquisition, Schneider Electric, Écu, Car, Wheel speed sensor, Bipolar, Video game, Marketing, Consumer electronics, Instrumentation

DUBLIN, Jan. 20, 2023 /PRNewswire/ -- The "Speed Sensor Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 20, 2023 /PRNewswire/ -- The "Speed Sensor Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global speed sensor market.
  • The main types of the speed sensor market are inductive sensor, monopolar, bipolar, and active sensor.
  • The regions covered in the speed sensor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

North America Silicon EPI Wafer Market Report 2023: Sector to Reach $1.17 Billion by 2028 with an 8.5% CAGR

Retrieved on: 
Thursday, January 19, 2023
EPI, COVID-19, LED, Epitaxy, Tablet, Silicon, MOS, Bipolar, Diffusion, Growth, Health, Center for Urban and Regional Analysis, Electronics, Computer, Gallium nitride, Shin-Etsu Chemical, MEMS, QST, Borosilicate glass

An epitaxial wafer, also known as an EPI wafer, is created by placing a layer of epitaxial silicon single crystal on a single crystal silicon wafer.

Key Points: 
  • An epitaxial wafer, also known as an EPI wafer, is created by placing a layer of epitaxial silicon single crystal on a single crystal silicon wafer.
  • This is likely to drive the North America silicon EPI wafer market at a notable CAGR during the forecast period.
  • The North America silicon EPI wafer market is segmented on the basis of wafer size, application, end user, type, and country.
  • Based on country, the North America silicon EPI wafer market is segmented into the US, Mexico, and Canada.

Electrosurgical Devices Global Market Report 2022: Increasing Demand for Minimally Invasive Surgeries Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Surgery, Health, Medical Devices, Cardiovascular disease, Ageing, Infection, AARP, Medical tourism, Personality, Government, Angioplasty, Bipolar, Argon, Diagnosis, Growth, European Society of Cardiology, Prevalence, Software, American Heart Association, Intensive care medicine, Chronic condition, Conditional sentence, Medical device, Health insurance

Chronic diseases are on the rise worldwide and increasing the need for minimally invasive surgeries to be performed within short duration.

Key Points: 
  • Chronic diseases are on the rise worldwide and increasing the need for minimally invasive surgeries to be performed within short duration.
  • Electrosurgical devices renders safe and cost effective surgeries, with early recovery period and less chances of infection after the surgery.
  • Factors such as minimally invasive procedures, technological advancement in surgical procedures and diverse application to perform surgeries promotes the demand for the electrosurgical devices market.
  • However, factors such as developing health infrastructure, increasing awareness and demand for minimally invasive surgeries are going to fuel the rapid growth of electrosurgical devices market in Latin America and Middle East and Africa region in the near future.

$10+ Billion Worldwide Speed Sensor Industry to 2031 - Increase in the Production of Vehicles Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Aftermarket, Automotive, Benchmark, Analog Devices, Maxim Integrated, Extrinsic semiconductor, ABB, Create, India Brand Equity Foundation, Wheel speed sensor, NXP Semiconductors, Écu, Travel, Rotation, Organization, Bipolar, Car, Growth, Health, Electronics, Infineon Technologies, Coronavirus, Sensor, Allegro, STMicroelectronics, TE, Schneider Electric, Acquisition, Sick AG, Rockwell Automation, Renewable energy, Instrumentation, Marketing

This report provides strategists, marketers and senior management with the critical information they need to assess the global speed sensor market.

Key Points: 
  • This report provides strategists, marketers and senior management with the critical information they need to assess the global speed sensor market.
  • The main types of the speed sensor market are inductive sensor, monopolar, bipolar, and active sensor.
  • An increase in the production of vehicles is expected to drive the speed sensor market going forward.
  • Therefore, the increase in the production of vehicles is driving the growth of the speed sensor market.

North America Silicon EPI Wafer Market Report 2023: Rising Demand for Epitaxial Wafers in Consumer Electronics Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 12, 2023
Technology, Hardware, Semiconductor, Consumer Electronics, EPI, COVID-19, LED, Epitaxy, Tablet, Silicon, MOS, Bipolar, Diffusion, Growth, Health, Center for Urban and Regional Analysis, Electronics, Computer, Gallium nitride, Shin-Etsu Chemical, MEMS, QST, Borosilicate glass

An epitaxial wafer, also known as an EPI wafer, is created by placing a layer of epitaxial silicon single crystal on a single crystal silicon wafer.

Key Points: 
  • An epitaxial wafer, also known as an EPI wafer, is created by placing a layer of epitaxial silicon single crystal on a single crystal silicon wafer.
  • The North America silicon EPI wafer market is segmented on the basis of wafer size, application, end user, type, and country.
  • By end user, the North America silicon EPI wafer market is segmented into consumer electronics, automotive, healthcare, aerospace and defense, and others.
  • Based on country, the North America silicon EPI wafer market is segmented into the US, Mexico, and Canada.

Pixium Vision announces peer-reviewed publications demonstrating the potential of the Next Generation PRIMA implant to restore vision at five times higher resolution than current implant

Retrieved on: 
Thursday, January 12, 2023
Diamond, Retinal degeneration, Visual impairment, PRIMA, Severe cognitive impairment, CET, Nature Communications, Stanford University, AMD, Hope, Human, Bipolar, Vance DeGeneres, Patient, Retina, Visual acuity, Journal, Neuron, Nervous system, Pixel, Mnemos EP, RATS, Electrode, Telescopic sight, Television, Medical device, Camera, Dentistry, Ophthalmology

Pixium Vision is developing the second generation of PRIMA implants in collaboration with its long-term academic partner Stanford University.

Key Points: 
  • Pixium Vision is developing the second generation of PRIMA implants in collaboration with its long-term academic partner Stanford University.
  • "Our new second generation PRIMA implant represents a huge leap forward in prosthetic vision and offers a real chance to restore sight close to natural vision in patients blinded by retinal degeneration," said Lloyd Diamond, Chief Executive Officer of Pixium Vision.
  • They are based on the design of the original PRIMA implants, which were also co-developed by Pixium Vision and Stanford University.
  • A resolution of 24mm on the retina corresponds to 5 times higher acuity than the clinical average with the current implant, promising a significant improvement of central vision for many AMD patients.

HMP Global's Psych Congress launches NP Institute In-Person event, new educational offering specifically for psychiatric nurse practitioners

Retrieved on: 
Tuesday, December 13, 2022
VRTX, APRN, EMT, LINC, Chicago, Bipolar, Schizophrenia, Learning, Health, Patient, Nursing, RN, Hunger, Stabilizer (aeronautics), Anxiety, Committee, University of Illinois at Chicago, Evolution, MS, Knowledge, Family, Symposium, SAWC, Psychiatry, NPS, University of California, Mental health, EMS, Practice management, News, Psych, University, Education, Documentation, NP, Mental disorder, Psychopharmacology, Congress, Depression, ADHD, CNS, Practitioner, Medicine, Pharmaceutical industry, Doctor of Philosophy, Psychotherapy

MALVERN, Pa. , Dec. 13, 2022 /PRNewswire-PRWeb/ -- Nurse practitioners in the psychiatric field have a robust new opportunity to grow their knowledge of psychopharmacology through the Psych Congress NP Institute In-Person event, featuring an interactive educational program which takes a deep dive into foundational principles and terminology on treatment, disease states, and medication classes.

Key Points: 
  • The inaugural Psych Congress NP Institute In-Person event will take place April 28 May 1 in Boston.
  • This essential educational experience is crafted by the world-class experts of Psych Congress, the United States' largest independent mental health educational conference and a forum for the entire mental health team.
  • The Psych Congress NP Institute In-Person event will help grow that confidence and a solid footing for building their psychopharmacological practice and provide resources for ongoing education for years to come."
  • For 36 years, Psych Congress has delivered practical, case-based education to an exceptional community of mental healthcare providers across the U.S.

BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference

Retrieved on: 
Thursday, December 1, 2022
Dexmedetomidine, Schizophrenia, Dementia, Bipolar II disorder, Event, Conference, Agitation, Artificial intelligence, Therapy, Bank, Patient, Bipolar, Prostate cancer, Safety, Algorithm, Thought disorder, Pharmaceutical industry, HAVEN

A webcast replay will be available on the Companys website following the event for 90 days.

Key Points: 
  • A webcast replay will be available on the Companys website following the event for 90 days.
  • BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
  • The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose.
  • All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, the date, time and content of the Companys fireside chat at the Bank of America 2022 Biotech SMID Cap Conference.

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

Retrieved on: 
Wednesday, November 30, 2022
Dexmedetomidine, Growth, Marketing, Trauma, Schizophrenia, Dementia, Bipolar II disorder, Food, Bipolar disorder, Agitation, Artificial intelligence, Therapy, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bipolar, Sleep, Drug Quality and Security Act, Coercion, Drug development, PEC, Breakthrough therapy, Aggression, Prostate cancer, Failure, II, Drug discovery, Algorithm, Safety, Thought disorder, Pharmaceutical industry, Neuroscience

NEW HAVEN, Conn., Nov. 30, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that the first 13 patients have been dosed in Part 1 of the pivotal Phase 3 SERENITY III trial investigating at-home use of BXCL501 (dexmedetomidine) sublingual film, the Company’s proprietary, orally dissolving film, for agitation associated with bipolar I or II disorder or schizophrenia.

Key Points: 
  • We anticipate top-line data from SERENITY III as well as our TRANQUILITY II trial for Alzheimers-related agitation in the first half of 2023.
  • SERENITY III is a two-part, double-blinded, placebo-controlled pivotal study designed to evaluate BXCL501 60mcg dose for at-home use.
  • SERENITY III will utilize many of the same investigators and clinical sites as SERENITY I and II.
  • BXCL501 is under investigation for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting, for the acute treatment of Alzheimers-related agitation, and as an adjunctive treatment for major depressive disorder.

BioXcel Therapeutics to Present at Two Upcoming Investor Conferences

Retrieved on: 
Monday, November 14, 2022
Thought disorder, Agitation, Bipolar II disorder, Dementia, Algorithm, Therapy, Prostate cancer, Patient, Conference, Safety, Neurology, Dexmedetomidine, Artificial intelligence, Schizophrenia, Bipolar, Guggenheim, Pharmaceutical industry, HAVEN

They will also discuss the Companys ongoing commercial launch strategy for IGALMI (dexmedetomidine) sublingual film.

Key Points: 
  • They will also discuss the Companys ongoing commercial launch strategy for IGALMI (dexmedetomidine) sublingual film.
  • BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
  • The safety and effectiveness of IGALMI has not been established beyond 24 hours from the first dose.
  • These forward-looking statements should not be relied upon as representing the Companys views as of any date subsequent to the date of this press release.